Navigation Links
Many breast cancer patients take high doses of antioxidants despite possible consequences
Date:6/7/2009

A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown. Published in the July 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that additional research should be undertaken to determine the effects of antioxidant supplementation on the health and survival of breast cancer patients.

Antioxidant supplements include vitamin C, vitamin E, beta-carotene, and selenium. They are found in individual supplements as well as in many multivitamins. Many breast cancer patients believe that antioxidant supplements will protect them from the side effects of breast cancer treatment, help prevent breast cancer recurrence, and improve their overall health. However, the actual effects of taking antioxidants during cancer treatment are poorly understood and the findings to date are mixed. Some physicians believe antioxidants may in fact interfere with radiation and some types of chemotherapy, which often attacks tumor cells by generating reactive oxygen species (ROS), very small molecules that play a role in cell development.

Researchers led by Heather Greenlee, ND, PhD, Assistant Professor of Epidemiology and Medical Oncology (in Medicine) at Columbia University Mailman School of Public Health in New York, investigated the prevalence of antioxidant use in women with breast cancer who participated in the population-based Long Island Breast Cancer Study Project (LIBCSP). LIBCSP, which included more than 1,500 breast cancer patients, began as a federally mandated study that investigated whether breast cancer risk was associated with environmental exposures among women in Nassau and Suffolk counties in New York State. Dr. Greenlee's study is based on the 764 patients who completed a follow-up interview and provided information on antioxidant supplement use.

Among the 764 patients studied, 663 women (86.8 percent) reported receiving chemotherapy, radiation, or hormone therapy for breast cancer. Of these 663 women, six in ten (60.5 percent) reported using antioxidants during breast cancer treatment, which included chemotherapy, radiation, and tamoxifen (anti-estrogen) therapy.

About seven in ten antioxidant users (69.3 percent) used high doses, defined as higher than the dose contained in a Centrum multivitamin. Women who took high doses of antioxidants during treatment were more likely to be using tamoxifen and to have a history of eating more fruits and vegetables, using herbal products, and engaging in mind-body practices.

"Given the common use of antioxidant supplements during breast cancer treatment, often at high doses and in conjunction with other complementary therapies, future research should address the effects of antioxidant supplementation on breast cancer outcomes," including whether antioxidants affect treatment toxicities, treatment efficacy, cancer recurrence, and survival, say the authors.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: